// App-Quantinova.ai

BSH2020‐EP‐071 : Indirect treatment comparison analysis of venetoclax + obinutuzumab with standard front‐line regimens for chronic lymphocytic leukaemia

Researchers

Presenter

  • N. Coll Bastus

Principal Investigators

  • M. S. Davids

  • S. F. Huntington

  • C. Moreno

  • G. Follows

  • A. Cuneo

  • K. Humphrey

  • W. Schary

  • K. Sail

  • Y. Song

  • Z. Gao

  • Z. Tang

  • G. Pena

  • R. Fo

  • P. Hillmen

Medical Centers

  • AbbVie Inc., Maidenhead, UK

  • Dana-Farber Cancer Institute, Boston, MA

  • Yale University, New Haven, CT

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • St. Anna University Hospital, Ferrara, Italy

  • Roche Products Limited, Welwyn Garden City

  • AbbVie, Inc., North Chicago, IL

  • Sapienza University, Rome, Italy

  • StJamess University Hospital, Leeds, UK

Locations

  • United Kingdom

  • United States

  • Spain

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • chlorambucil

  • fludarabine tablet

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • III

Study Id's

  • NCT0295005

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved